Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SLC-391 |
Synonyms | |
Therapy Description |
SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SLC-391 | SLC391|SLC 391 | AXL Inhibitor 30 | SLC-391 is an Axl inhibitor that blocks the phosphotransferase activity of Axl, which potentially stimulates anti-tumor immune response and reverses immunosuppression leading to tumor growth inhibition (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B148). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03990454 | Phase I | SLC-391 | Safety Study of SLC-391 in Subjects With Solid Tumors | Completed | CAN | 0 |